On Friday, The Timken Company (NYSE:TKR)’s shares declined -3.35% to $40.38.
On April 16, The Timken Company (TKR), will release its 2015 first-quarter financial results on Thursday, April 30, 2015, preceding to the opening of the New York Stock Exchange.
The company will host a conference call that day to talk about its financial performance with investors and securities analysts. The financial results and conference call materials will be accessible online at www.timken.com.
Conference Call:
Thursday, April 30, 2015
11:00 a.m. Eastern Time
Live Dial-In: 888-778-9065
Conference ID: Timken Earnings Call
Conference Call Replay:
Replay Dial-In accessible through
May 14, 2015:
888-203-1112 or 719-457-0820
Replay Passcode: 7158396
Live Webcast: www.timken.com/investors
The Timken Company engineers, manufactures, and markets bearings, transmissions, gearboxes, and chain and related products worldwide. It operates in two segments: Mobile Industries and Process Industries. The Mobile Industries segment offers a portfolio of bearings, seals, lubrication devices, and systems, in addition to power transmission components, engineered chain, augers, and related products and maintenance services to original equipment manufacturers (OEMs) of off-highway equipment for the agricultural, construction, and mining markets.
At the end of Friday’s trade, Transocean Ltd. (NYSE:RIG)‘s shares dipped -3.33% to $17.98.
On April 16, Transocean Ltd. (RIG), issued a comprehensive Fleet Status Report which provides the current status of and contract information for the company`s entire fleet of offshore drilling rigs. The total value of new contracts since the March 18, 2015 Fleet Update Summary is about $26 million.
The report comprises the following:
- Sedco Express - Awarded a 45-day contract extension offshore Nigeria at a dayrate of $300,000 ($14 million estimated backlog).
- GSF Galaxy II - Awarded a two month contract extension in the U.K. sector of the North Sea at a dayrate of $190,000 ($12 million estimated backlog).
- Sedco Energy - The customer has elected to release the rig; the contract provides for a payment to the company in the event of an early termination.
- The Discoverer Enterprise, Sedco Energy, Transocean Amirante, and GSF Galaxy III are idle.
Estimated 2015 out-of-service time reduced by a net 59 days primarily due to GSF Rig 140. The company is presently committed to about 48 days of planned out-of-service time in 2016.
Transocean Ltd., together with its auxiliaries, provides offshore contract drilling services for oil and gas wells worldwide. The company primarily offers deepwater and harsh environment drilling services. As of February 17, 2015, it owned or had partial ownership interests in, and operated 71 mobile offshore drilling units that comprise of 44 high-specification floaters, 17 midwater floaters, and 10 high-specification jackups.
Synta Pharmaceuticals Corp. (NASDAQ:SNTA), ended its Friday’s trading session with -3.30% loss, and closed at $2.93.
On April 16, Synta Pharmaceuticals Corp. declared recently that poster presentations related to studies with ganetespib, a novel, potent small molecule inhibitor of heat shock protein 90 (Hsp90) in Phase 3 development, and STA-12-8666, the company’s leading candidate from its proprietary Hsp90 inhibitor Drug Conjugate (HDC) Program, will be presented at the 2015 Annual Meeting of the American Association of Cancer Research (AACR) in Philadelphia, Pennsylvania.
“Preclinical data presented at this year’s AACR meeting add to the body of data supporting the potential benefit of combining ganetespib with multiple therapeutic modalities in the treatment of various cancers, counting non-small cell lung cancer. These data continue to provide support for our broad clinical strategy, counting the ongoing Phase 3 GALAXY-2 trial and our large, randomized, investigator-sponsored studies, and will assist shape our future clinical direction,” said Anne Whitaker, President and Chief Executive Officer of Synta. “In addition, we continue to see highly encouraging preclinical proof of concept data for our lead HDC candidate, STA-12-8666, in several animal models, counting resistant pancreatic cancer and small cell lung cancer patient derived xenografts. We are encouraged by the progress of this program and look forward to moving toward an IND submission by the first quarter of 2016.”
Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on the research, development, and commercialization of novel oncology medicines for cancer patients. Its lead oncology drug candidate comprises ganetespib, an Hsp90 inhibitor, which is in Phase III clinical trial for the treatment of non-small cell lung cancer; in Phase II clinical trial for patients with hormone receptor positive metastatic breast cancer; in Phase I clinical trial for the treatment of HER2 positive patients with metastatic breast cancer; in Phase II/III clinical trial for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome; in Phase I/II trial of paclitaxel in combination with ganetespib in patients with platinum-resistant ovarian cancer; and in Phase I/II trial in combination with the mTOR inhibitor sirolimus in patients with refractory sarcoma.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
